Johnson & Johnson Finalizes $3.05 Billion Purchase of Halda Therapeutics, Expanding Oncology Pipeline
New Brunswick, N.J.—Johnson & Johnson has closed the $3.05 billion cash acquisition of Halda Therapeutics, bringing the biotechnology company’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform and a series of investigational cancer medicines into the healthcare group’s innovative medicine segment. The transaction, completed on 30 December 2025, follows a definitive agreement signed in November. By […]